Herantis Pharma Oyj Management

Management criteria checks 2/4

Herantis Pharma Oyj's CEO is Antti Vuolanto, appointed in Jul 2022, has a tenure of 2.33 years. directly owns 0.012% of the company’s shares, worth €2.96K. The average tenure of the management team and the board of directors is 4.1 years and 3.6 years respectively.

Key information

Antti Vuolanto

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.3yrs
CEO ownership	0.01%
Management average tenure	4.1yrs
Board average tenure	3.6yrs

Recent management updates

Recent updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

CEO

Antti Vuolanto (49 yo)

2.3yrs

Tenure

Dr. Antti Vuolanto, D.Sc. (Tech) serves as Chief Executive Officer of Herantis Pharma Oyj since July 2022. He served as Chief Operating Officer at Herantis Pharma Oyj since February 2018. Dr. Vuolanto serv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Antti Vuolanto	Chief Executive Officer	2.3yrs	no data	0.012% € 3.0k
Tone Kvale	Chief Financial Officer	4.1yrs	no data	0.056% € 14.2k
Henri Huttunen	Chief Scientific Officer	14.8yrs	no data	0.40% € 100.8k
Jani Koskinen	Head of CMC	no data	no data	no data
Outi Lahdenperä	Chief Medical Ofcer	no data	no data	no data
Charlotte Videbaek	Clinical Consultant	no data	no data	no data

4.1yrs

Average Tenure

55yo

Average Age

Experienced Management: HRTIS's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Aki Prihti	Director	10.8yrs	no data	0.0079% € 2.0k
Anders Pedersen	Chairman of Scientific Advisory Board	3.2yrs	no data	no data
Timo Veromaa	Independent Chairman of the Board	12.8yrs	no data	0.076% € 19.3k
Mats Thoren	Director	4.6yrs	no data	no data
Frans Wuite	Director	10.8yrs	no data	0.14% € 34.6k
Alberto Espay	Member of Scientific Advisory Board	3.1yrs	no data	no data
Hilde Furberg	Director	3.6yrs	no data	0.0099% € 2.5k
David Dexter	Member of Scientific Advisory Board	3.1yrs	no data	no data
Daniele Bravi	Member of Scientific Advisory Board	3.1yrs	no data	no data

3.6yrs

Average Tenure

65yo

Average Age

Experienced Board: HRTIS's board of directors are considered experienced (3.6 years average tenure).

Herantis Pharma Oyj Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Oyj Announces Nomination Committee Appointments

Recent updates

Herantis Pharma Plc Starts Dosing of HER-096 in the Part 1 of the Phase 1b Clinical Trial

Herantis Pharma Oyj to Report Fiscal Year 2023 Results on Mar 27, 2024

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €4.506795 million.

Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096

Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study

Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096

Herantis Pharma Oyj Announces Submission of A Clinical Trial Application (CTA) for A Phase 1 Study for HER-096

Herantis Pharma Oyj to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Herantis Pharma Applies for Delisting from Nasdaq First North Growth Market Sweden

Less than half of directors are independent

Herantis Pharma Oyj to Report Second Half, 2022 Results on Mar 02, 2023

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €1.4625 million.

Herantis to Focus on HER-096

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology

Herantis Pharma Announces xCDNF Preclinical Candidate Selection

Earnings beat expectations

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Herantis Pharma Plc Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema

New 90-day low: €3.28

Herantis Pharma Oyj and Nanoform Enter into Agreement for Proof of Concept Collaboration

Herantis Pharma Oyj Announces Nomination Committee Appointments

Herantis Pharma plc Appoints Magnus Sjögren as Chief Medical Officer, Effective May 1, 2021

Herantis Pharma Oyj to Report Fiscal Year 2020 Final Results on Mar 25, 2021

New 90-day low: €3.90

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® Trial in Breast Cancer Associated Lymphedema

New 90-day low: €4.83

Ingrid Heiman to Leave Herantis Pharma's Board of Directors

Herantis Pharma Plc Appoints Tone Kvåle as Member of the Management Team

New 90-day low: €6.82

New 90-day low: €7.24

Herantis Pharma Oyj to Report Fiscal Year 2020 Results on Mar 03, 2021

New 90-day high - €8.86

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age